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Abstract
Objective To evaluate a training intervention aimed at
improving healthcare professionals’ communication with
cancer patients about randomised clinical trials.
Design Before and after evaluation of training programme.
Setting Members of the National Cancer Research Network,
Scottish Trials Network, and the Welsh Cancer Trials Network
Participants 101 healthcare professionals (33 clinicians and 68
research nurses).
Intervention Four modules delivered by a trained facilitator
using videotapes and interactive exercises to cover general
issues about discussing randomised clinical trials with patients,
problems specific to adjuvant trials, trials with palliation as the
goal, and trials where patients had a strong preference for one
treatment arm.
Main outcome measures Before and after the intervention,
participants were videotaped discussing a trial with an actor
portraying a patient. These consultations were assessed for
presence of information required by good clinical practice
guidelines. The actor patients gave an assessment after each
interview. Participants reported their self confidence about key
aspects of trial discussion.
Results Analysis of the videotaped consultations showed that,
after intervention, significantly more participants displayed key
communication behaviours such as explaining randomisation
(69 v 81, odds ratio 2.33, P = 0.033), checking patients’
understanding (11 v 31, odds ratio 3.22, P = 0.002), and
discussing standard treatment (73 v 88, odds ratio 4.75,
P = 0.005) and side effects (69 v 85, odds ratio 3.29, P = 0.006).
Participants’ self confidence increased significantly (P < 0.001)
across all areas. Actor patients’ ratings of participants’
communication showed significant improvements for 12/15
key items.
Conclusion This intensive 8 hour intervention significantly
improved participants’ confidence and competence when
communicating about randomised clinical trials.
Introduction
Worldwide fewer than 5% of eligible patients with cancer partici-
pate in randomised clinical trials, limiting the progress of cancer
research. In Britain healthcare professionals are under pressure
from various bodies to recruit more patients into such trials.1
Various publications provide guidance about trial conduct and
the standards expected for good clinical practice,2 but few help
clinicians in their discussions with patients.3 Reference is made to
the importance of communication with patients, especially with
regard to informed consent, but research has shown that few cli-
nicians feel skilled in this task.More than 52% of senior clinicians
attending communication skills courses and 27% of chemo-
therapy nurses acknowledged that providing complex informa-
tion and seeking consent to clinical trials were their main
communication problems, surpassing even the breaking of bad
news.4
In discussing randomised clinical trials, a healthcare
professional must discuss standard treatment, the logic for a
trial, the uncertainty about new drugs or procedures, and the
potential benefits and harms of the different treatments, as
well as explain the concept of randomisation and other
terms such as double blind or placebo controlled. If communi-
cation is inadequate patients may not understand the
experimental nature of the trial, be unclear about treatment
options outside a trial setting, and be unable to give truly
educated consent.5
One study of the content of discussions about randomised
trials between clinicians and patients reported that, despite the
stated requirements of trial protocols, clinicians adopted
idiosyncratic methods when providing trial information.6
Although most discussed the different treatments on offer and
associated side effects in great detail, they often gave minimal
reasons for randomisation.
A recent survey of 190 patients enrolled in double blind pla-
cebo controlled trials showed that they did not fully understand
certain aspects of trial recruitment even though they felt satisfied
with the information provided.7 Understanding more about
patients’ reasons for trial participation or refusal and their
knowledge about trials helped increase recruitment in one
particular study. Researchers applied their findings to improve
the recruitment rate from 30% to 70%.8 Use of more effective
communication techniques may be another method of ensuring
better understanding and decision making and improving
recruitment to trials.
After requests for training materials, we designed a compre-
hensive educational programme to help health professionals
when communicating about randomised trials. Many otherwise
laudable communication skills courses, guidelines, and educa-
tional programmes lack any objective evaluation.9 Therefore,
before launching a national training programme, we evaluated
its efficacy and acceptability with UK health professionals
engaged in trial recruitment.
Further details of the conditional logistic regression used in the study are
on bmj.com
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Participants and methods
Participants
We sent a general letter of invitation to the National Cancer
Research Network, Scottish Trials Network, and the Welsh Can-
cer Trials Network inviting healthcare professionals to attend
our training course: 103 enrolled in the study, but one research
nurse became ill during the course and another withdrew. Table
1 shows the characteristics of the remaining 33 clinicians and 68
research nurses or radiographers. Although nearly all
participants had previously received communication skills
training, many (31 clinicians and 23 nurses) had not attended a
good clinical practice guideline course.
Before attending our course, participants nominated a
trial in which they were currently involved which would be
used in their videotaped consultations. Almost half the group
(48%) chose a trial comparing standard treatment with a
new treatment, 22% chose a trial that had a “no extra treatment”
arm (such as surgery with or without preoperative chemo-
therapy), 18% chose a trial with a placebo arm, 9% chose a trial
that had a “toxic” or high dose arm, and 3% chose a surgical
trial.
Course contents
Our course lasted eight hours, split over two days. The course
comprised interactive exercises, didactic presentations, and
facilitated discussion about the videotaped scenarios in the mod-
ules. During the course, we encouraged participants to consider
how they structured trial discussions with patients and how they
described treatments available on and off trial and the process of
randomisation, and to compare these with those depicted in the
modules. At the end of the course participants generated a list of
key points about trial discussion.
Course materials
We developed the training materials in close collaboration with
experienced doctors, research nurses, trial managers, and
patient groups. We had to conduct original research in several
subjects such as patient preferences for different descriptions of
randomisation as evidence based recommendations did not
exist.10 The training materials comprised four video modules
(see fig 1), a CD Rom, and a comprehensive facilitator’s
handbook.
Module 1 provides a generic introduction to randomised
clinical trials and includes comments by six patients, eight clini-
cians, a research nurse, and a trial manager exploring the
difficulties associated with discussing trials.
Module 2 deals with the discussion of adjuvant treatment tri-
als and contains two scenarios—VICTOR, a placebo controlled
colorectal cancer trial, and the intergroup exemestane study
(IES), a breast cancer trial. This module also looks at handling
uncertainty and dealing with uninformed and suspicious
patients.
Module 3 includes two scenarios of palliative trials—Myeloma
VII, a multiple myeloma trial, and the big lung trial (BLT) for
non-small cell lung cancer. This module promotes discussion
about handling deferential patients and their more questioning
relatives and giving distressed patients complex information
about highly toxic treatment.
Module 4 depicts patients who may have a strong preference
for a particular treatment arm and explores how to handle
patients with high information needs who have collected many
internet articles and newspaper cuttings—in the MRC CLASICC
trial, a surgical trial for bowel cancer, and MRC PRO7, a prostate
cancer trial.
All four modules have a linking commentary and statements
by clinicians and nurses.
The facilitator handbook was developed for use by both
experienced and less experienced facilitators. It contains a time
coded commentary about the issues shown in the accompany-
ing videotapes and suggestions about appropriate places to stop
and engage a group in exercises or discussion. It provides
examples of how to structure a teaching session and a
bibliography of relevant reading materials. The CD Rom
contains questionnaires, handouts about the trials described in
the videos, a bibliography, group exercises, and PowerPoint
presentations for the didactic work showing the evidence base
for suggestions made.
Videotaped consultations
Before and after the course, we videotaped participants
conducting simulated discussions with patients about
clinical trials. The actors who portrayed the patients were
experienced in improvisation as “cancer patients” and were
well briefed about their disease, its symptoms, and the trial
being discussed. The actors were assigned one of four different
characters; the patient who comes armed with newspaper
clippings and web reports on cancer treatments (internet guru),
the patient who has already decided which treatment he
or she wishes to receive (preference), the patient who
defers decisions about trial participation to the nurse or
clinician (deferential), and the patient who is uneasy about
trials (suspicious). To enhance authenticity, we used different
Table 1 Details of participants’ characteristics and previous experience of
communication skills training. Values are numbers of participants
Clinicians (n=33) Nurses or radiographers (n=68)
Men 18 3
Women 15 65
Consultants 23 0
Specialist registrars 10 0
Previous communication
skills training:
32 67
Undergraduate 21 50
Postgraduate 26 47
GCP guideline course 2 45
GCP=Good clinical practice.
Fig 1 Example of the scenarios depicted in the training videos. In module 3
Professor Peter Selby explains the Myeloma VII trial to the distressed patient
“Sheila” with the research nurse present
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actors in each participant’s initial and post-course discussion,
but the patient characteristic and the trial remained
constant.
Thirty three participants conducted two videotaped patient
interviews before the course, so that we could check for any
practice effect in performing the interview twice.
Assessments
Before and after the training course, participants rated their self
confidence on a scale from 0 (none) to 10 (very confident) about
general aspects of discussing trials with patients. Items included
describing randomisation, discussing different types of trials
(such as placebo controlled), and handling discussions with chal-
lenging patients (such as the suspicious, demanding, or overly
anxious).
We objectively assessed participants’ videotaped interviews.
The data manager of the unit assigned a random number to each
tape, and the assessment was done by one of the authors (VJ),
who was not involved with filming the interviews and was there-
fore blinded to whether they were before or after the training
course. Analysis involved checking for the presence of key infor-
mation as stated in the good clinical practice and ethical
guidelines—for example, the voluntary nature of trials, explicit
use of the term randomisation, and descriptions of side effects.
We also assessed specific behaviours against pre-set criteria—
such as checking patients’ understanding and summarising
information.
After each videotaped interview, the actor “patients”
completed a 15 item questionnaire about whether they had
understood the explanation of randomisation, were told that
participation was voluntary, and other communication issues.
The questionnaire had a Likert-type scale of 0-4 (0 = not at all,
1 = a little, 2 = somewhat, 3 = quite a bit, 4 = very much).
Hypotheses
Our a priori hypotheses were that
x Participants’ communication in key areas of discussions about
clinical trials would improve after the course—that is,
competence would be measurably better
x Participants would feel more confident about discussing trials
and about approaching different types of patients after the
course—that is, self confidence would be enhanced.
Statistical methods
We analysed the data generated from the video analysis using
conditional logistic regression models in order to compare the
scores reported for each participant before and after the course.
The analysis was based on binary (yes/no) variables derived from
either a yes/no score or by defining yes to be “Very well” or
“Reasonably well” and no to be “Not at all” or “Not very well”
from a four level score. We estimated odds ratios, with values > 1
indicating that a “yes” score was more likely in the interview after
the course and that participants’ behaviour had improved after
the course.
We defined scores for the actors’ questionnaire responses as
one for “Not at all” or “A little bit”, two for “Somewhat,” and three
for “Quite a bit” or “Very much.” An odds ratio > 1 represents a
shift towards upper categories after the course. The scores from
the participants’ confidence questionnaire were used directly,
and an odds ratio > 1 indicates a shift towards higher levels of
confidence after the course.
Formally, all odds ratios represent, for two observations from
the same individual differing by one unit, the relative odds of the
larger value being after the course compared with before the
course. No distributional assumptions are required for the
scores. Thus, the conditional logistic model used here provides a
Information item
Purpose of interview defined
Research nurse or doctor referred to
Type of trial discussed
Study defined as research
Voluntary participation explained
Randomisation explained
Patient's understanding of randomisation checked
Use of analogy to describe randomisation
Withdrawal from study explained
Uncertainty about treatment expressed
Standard treatments discussed
Treatments explained
Side effects discussed
Participant summarised discussion
Patient encouraged to:
  Ask questions
  Discuss options with family
  Read the information sheet
"Won't hurt my feelings if you don't participate"
"Will benefit other patients in the future"
"Won't hurt my feelings if you withdraw from the study"
"It could be of benefit to you"
"Others participated in the past"
"Patients do better in trials"
0 1 2 3 4 5 6 7 8
Odds ratio
Fig 2 Odds ratios (95% confidence intervals) of improved scores after the training course for the presence of key information in participants’ videotaped interviews
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robust method for before and after comparisons. The key data
for estimation purposes are the number of participants with dif-
ferent scores at the two time points. Large positive odds ratios
occur when more shifts occur towards yes, or larger values, than
towards no, or smaller values.
Results
We found no evidence of practice effects in the two videotaped
interviews performed by 33 participants before the training
course. On 108 occasions a participant scored a “yes” on a ques-
tion for the second interview and a “no” for the first interview
and on 112 occasions a participant scored “no” for the second
interview and “yes” for the first. Thus, in the absence of evidence
for practice effects, our final analysis for the whole sample was
based on the initial interview before the course.
Video analysis—We examined rater reliability for 10% of the
videotapes and found good agreement in rating of interviews
conducted before and after the course (= 0.664 (SE 0.025)).
Figure 2 and table 2 show the odds ratios for the video analysis.
For example, with the item “Is patient’s understanding of the
term randomisation checked?” the odds of a “yes” score were
3.22 times higher after the course than before the course. Many
important communication behaviours specific to trial discus-
sions improved significantly. After the course, more participants
described the particular type of trial “very well” (81 v 91), gave
clear explanations about the treatments available on and off trial
(73 v 88) and their side effects (69 v 85), and explained the term
randomisation (69 v 81) but used fewer analogies to do so (36 v
22). Participants also improved in checking that the patient had
understood the explanation of randomisation (11 v 31) and
showed some improvement in explaining the voluntary nature
of the trial (71 v 81, P = 0.08). However, some behaviours stated
in the good clinical practice guidelines, such as encouraging
patients to read the trial information sheet and informing them
that they could withdraw at any time did not alter significantly
(92 v 85 and 33 v 34, respectively).
Actor patients’ ratings—Figure 3 and table 3 show the odds
ratios for the actor’s responses to their questionnaire. For 12/15
statements the actors reported significant improvements after
the training course; this occurred despite the relatively high
positive baseline scores that influenced the lack of demonstrable
change for three statements (“I was left confused,” “The
healthcare professional seemed to favour one treatment over
another,” “I still have unanswered questions”).
For neither of these objective measures did the actor patients’
sex or character type affect the pattern of participants’ behaviour
Table 2 Odds ratios and P values of improved scores after the training course
for the presence of key information in participants’ videotaped interviews
Statements Odds ratio P value
Purpose of the interview defined 1.67 0.118
Research nurse (or doctor) referred to 3.25 0.039
Type of trial discussed (such as placebo, double blind, etc)* 2.43 0.048
The word “trial” or “study” mentioned explicitly* —† —†
Study defined explicitly as research* 0.67 0.374
Voluntary participation explained explicitly* 1.91 0.082
Concept of randomisation explained* 2.33 0.033
Patient’s understanding of the term randomisation checked* 3.22 0.002
Analogy or another expression used to describe the
randomisation process (such as 50:50)*
0.48 0.030
Withdrawal from study explained explicitly* 1.06 0.862
Uncertainty about treatment decisions expressed* 2.14 0.096
Treatment choices outside the trial (that is, standard treatment)
discussed*
4.75 0.005
Explanation given of what the treatment involves* 5.5 0.027
Side effects discussed* 3.29 0.006
Patient asked to summarise discussion —‡ 0.030‡
Participant summarises discussion 0.92 0.835
Patient encouraged to:
Ask questions* 1 1.000
Discuss options with family* 2.42 0.010
Read the information sheet* 0.53 0.151
Following messages given:
“Won’t hurt my feelings if you don’t participate” 1.15 0.706
“It will benefit other patients in the future” 0.83 0.602
“Won’t hurt my feelings if you withdraw from the study” 0.38 0.069
“It could be of benefit to you” 0.53 0.151
“Other patients in the past participated in trials” 1 1.000
“Patients do better in trials” 0.5 0.206
Is patient asked for a decision immediately* 0 1.000
*Recommended in good clinical practice guidelines.
†Not calculable since all participants mentioned word in all interviews.
‡Odds ratio infinity because all shifts were towards “yes.” P value was therefore calculated
with Fisher’s test of exact probability.
Information item
Healthcare professional used clear language
Voluntary participation explained
Understood could leave at any time
Understood randomisation
Healthcare professional sensitive
Encouraged to ask questions
Confused
Listened to
Understood treatment options
Side effects explained
Healthcare professional favoured one treatment
Heathcare professional gave me all information
Trusted healthcare professional
Given time to consider entry
Still have unanswered questions
0 1 2 3 4 5 6 7
Odds ratio
Fig 3 Odds ratios (95% confidence intervals) of improved scores after the training course for actor patients’ assessments of participants’ videotaped interviews
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changes, nor was there a relation with participant type (clinician
v research nurse or radiographers)
Participants’ self confidence—Figure 4 and table 4 show that par-
ticipants’ self confidence ratings increased significantly after the
training course for each statement at the P = 0.001 level. Despite
these improvements, several aspects of trial recruitment
remained challenging, including describing randomisation and
time constraints. Explaining multi-arm and phase I trials, which
were not portrayed in the training modules, remained problem-
atic for most participants.
Discussion
To our knowledge this is the first evaluation of an intervention
designed specifically to help health professionals provide clear
information about phase III randomised trials of cancer
treatments to patients and to encourage them to approach all
eligible patients for recruitment. The use of videos in health edu-
cation for patients and for training health professionals is now
common, but, although many are entertaining, they can encour-
age a passive audience, which leads to little learning. We
designed our modules to stimulate and provoke constructive dis-
cussion among viewers. The course integrated different activities
in order to create simultaneous rather than sequential skills
development and to stimulate knowledge acquisition and aware-
ness of how these affect patients and health professionals. This
model of communication allows participants to focus on their
own perceived areas of difficulty and makes the course work per-
tinent to their needs.11
We have used these types of “trigger” tapes successfully in our
previous research with nurses and doctors working in
oncology.4 11 The intervention reported here was valued highly
by all participants, who rated the course as useful, interesting,
informative, and enjoyable, and all stated they would
recommend participation to their colleagues.
The high priority given by the UK government to increase
patient recruitment into clinical trials alerted the national cancer
networks in England, Scotland, and Wales to health profession-
als’ need for training in this aspect of communication. The find-
ings from our study confirm that healthcare professionals can
benefit from structured advice and guidance about communicat-
ing about trials. Although several participants had undergone
some communication skills training, none had received specific
training on how to talk about trials.
The positive findings from the course included an increase in
participants’ reported self confidence about recruiting patients
into trials, and objective analyses revealed behavioural changes
in the style and content of the participants’ discussions. Some
researchers have suggested that behaviours changed during a
training course might not be transferred into clinical practice
without support or consolidation courses,12 13 but there is strong
evidence that if both competence and self confidence are
improved then behavioural changes often do transfer success-
fully into the clinical setting and endure.11 14
Table 3 Odds ratios of improved scores after the training course for actor
patients’ assessments of healthcare professionals’ videotaped interviews
Statement Odds ratio P value
The healthcare professional used clear and understandable
language
6.47 0.0018
I understood that entry into the trial is voluntary 3.29 0.002
I understood that if I agreed to take part I could leave the trial
at any time
1.50 0.032
I understood the explanation of randomisation 2.81 0.001
I felt the healthcare professional was sensitive to my concerns 1.80 0.02
I was given the opportunity to ask questions 1.70 0.013
I was left confused 1.29 0.22
I felt the healthcare professional listened to what I had to say 2.34 0.0048
I understood the treatment options available to me outside the
trial
1.55 0.014
I was told of the possible side effects of the different treatments 1.91 0.0032
The healthcare professional seemed to favour one treatment
over another
0.878 0.61
I felt the healthcare professional gave me all the information I
needed to make a decision
1.8 0.017
I felt the healthcare professional created an atmosphere of trust
and support
2.18 0.0051
I felt the healthcare professional gave me time to consider entry
into the trial
1.66 0.046
I still have unanswered questions 1.24 0.26
Information item
Discussing clinical trials
Describing randomisation
Have informed consent
Side effects explained
Giving complex information to:
  Highly intelligent patients
  Patients with limited ability to understand
Entering patients into:
  Placebo arm trials
  No treatment arm
  Highly toxic arm
  Trial with new treatment not available off trial
  Trial with new treatment available off trial
Dealing with:
  "Internet guru" patient
  Deferential patient
  Suspicious patient
  Patient with a preferred treatment
0 1 2 3 4 5 6
Odds ratio
Fig 4 Odds ratios (95% confidence intervals) of improved scores after the training course for participants’ self rated confidence
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Our training course is now being rolled out by the national
cancer research networks in England and Wales, and research to
see if real patient outcomes are affected is planned. Further
modules are being developed to deal with types of trials not
depicted in the existing modules—namely those for paediatric
and adolescent patients, screening and prevention trials,
multi-arm trials, and phase I studies.
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Table 4 Participants’ self confidence ratings before and after the training course and odds ratios of scores being improved (n=101)
Statement
Mean self confidence scores
Odds ratio P valueBefore course After course
How confident are you about discussing clinical trials with patients with cancer? 6.5 7.9 3 <0.001
How easy do you find describing randomisation? 6.5 7.5 1.69 <0.001
How confident are you that you really have informed consent from patients before starting treatment? 6.5 7.6 1.96 <0.001
How confident are you that you tell patients about the most likely side effects of treatment? 7.8 8.4 1.63 0.0011
How confident are you about providing complex information about trials to highly intelligent patients? 6.2 7.6 3.11 <0.001
How confident are you about providing complex information about trials to patients with limited ability to understand? 5.9 7.2 2.18 <0.001
How comfortable are you with entering patients into the placebo arm of trials? 5.8 6.6 1.45 <0.001
How comfortable are you with entering patients into trials that have a no treatment arm? 5.8 6.8 1.52 <0.001
How comfortable are you with entering patients into a trial that has a highly toxic treatment arm v standard treatment? 5.0 6.4 2.35 <0.001
How comfortable are you about recruiting patients into a trial comparing standard treatment v a new treatment or
procedure not available off trial?
6.2 7.6 2.38 <0.001
How comfortable are you about recruiting patients into a trial comparing standard treatment v a new treatment or
procedure that is available off trial?
6.3 7.1 1.47 <0.001
How confident are you in dealing with the “internet guru” patient? 5.7 7.6 3.53 <0.001
How confident are you in obtaining authentic informed consent from patients who have a deferential attitude towards you? 5.4 7.1 2.38 <0.001
How confident are you when discussing trials with patients who are mistrustful and suspicious about trials and
experiments in medicine?
5.7 7.0 2.28 <0.001
How confident are you when dealing with patients who object to being randomised and wish to choose their treatment arm? 6.1 7.3 1.94 <0.001
What is already known on this topic
Worldwide, few potentially eligible patients are approached
about entry into clinical trials; healthcare professionals find
discussing trials and obtaining truly informed consent
difficult
Patients are often confused or unclear about the
experimental nature of treatment in trials
What this study adds
A training course was designed specifically to help health
professionals provide clear information about phase III
randomised trials of cancer treatments to patients and to
encourage them to approach all eligible patients for
recruitment
The course increased participants’ reported self confidence
about recruiting patients into trials, and objective analyses
revealed improvements in the style and content of the
participants’ discussions
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